Salicylic Acids as Readily Available Starting Materials for the Synthesis of meta-Substituted Biaryls

Supporting Information

Junfei Luo,^{*a,b*} Sara Preciado^{*a*} and Igor Larrosa^{*b*,*}

^{*a*} School of Biological and Chemical Sciences, Queen Mary University of London, Mile End Road, London, E1 4NS, UK.

^b School of Chemistry, University of Manchester, Oxford Road, Manchester, M13 9PL, UK.

Table of Contents

General experimental information. *Page S2* Optimization tables. *Page S3* Procedures and characterization data. *Page S6* Derivatization of product **3ai**. *Page S18* Silver free arylation of salicylic acids. *Page S22* References. *Page S24* Spectroscopic data. *Page S25*

General experimental information

All chemicals used in this work were purchased from commercial sources and used without further purification, except 5-iodo-1-tosyl-1*H*-indole and 4-acetamido-2-hydroxybenzoic acid that were prepared following literature procedures.¹ Analytical thin-layer chromatography was performed on precoated Merk silica gel F_{254} plates and visualized under a UV light. Melting points were obtained using a Bibby Stuart Scientific apparatus and are uncorrected. IR spectra were recorded using a Bruker Tensor 37 FTIR machine and are quoted in cm⁻¹. ¹H NMR spectra, recorded at 400 MHz, are referenced to the residual solvent peak at 7.26 ppm (CDCl₃) and 2.05 ppm (acetone-d₆). ¹³C NMR spectra, recorded at 101 MHz, are referenced to the residual solvent peak at 77.0 ppm (CDCl₃) and 29.8 ppm (acetone-d₆).

Optimization tables



Table 1. Systematic screening of reaction conditions.^a

^a Unless otherwise noted, all reactions were carried out using 1.0 equiv of **1a**, 3.0 equiv of **2a** and 1.0 equiv of silver carbonate, yields were determined by ¹H NMR analysis using mesitylene as an internal standard.

 $^{\rm b}$ 200 μL of DMSO were also added.

^c 5.0 equiv of water were also added.

Table 2. Palladium catalysts screening.^a



^a Unless otherwise noted, all reactions were carried out using 1.0 equiv of 1a, 3.0 equiv of 2a, 1.0 equiv of silver carbonate and 200 µL (7.0 equiv) of acetic acid for 16 h at the temperature of 130 °C, yields were determined by ¹H NMR analysis using 1,3,5-trimethoxybenzene as an internal standard. b 1 mol% of Pd₂(dba)₃ was used .

^c 2 mol% of IMesCl were also added.

^d 2 mol% of IPrCl were also added.

Table 3. Silver salts screening.^a



Entries	AgX (1.0 equiv)	Yield of 3a (%)
24	Ag ₂ CO ₃	42
25	Ag_2O^b	38
26	AgOAc	41
27	AgNO ₂	0

^a Unless otherwise noted, all reactions were carried out using 1.0 equiv of 1a, 3.0 equiv of 2a, 2 mol% of Pd(OAc)₂, 200 μ L (7.0 equiv) of acetic acid, ran for 16 h at 130 °C, yields were determined by ¹H NMR analysis using 1,3,5-trimethoxybenzene as an internal standard. ^b0.5 equiv of silver oxide were used in the reaction.

Table 4. Solvent screening.^a



Entries	Solvent (200 µL)	Yield of 3a (%)
28	Acetic acid	56
29	TFA	54
30	Pivalic acid	28

^a Unless otherwise noted, all reactions were carried out using 1.0 equiv of **1a**, 3.0 equiv of **2a**, 2 mol% of PEPPSI-IPr and 1.0 equiv of silver carbonate, ran for 16 h at the temperature of 130 °C, yields were determined by ¹H NMR analysis using 1,3,5-trimethoxybenzene as an internal standard.

Table 5. Optimization of the formal meta-arylation using PEPPSI-IPr



^a Unless otherwise noted, all reactions were carried out using 1.0 equiv of **1a**, 3.0 equiv of **2a**, 2 mol% of PEPPSI-IPr, ran for 16 h, yields were determined by ¹H NMR analysis using 1,3,5-trimethoxybenzene as an internal standard.

 b 0.5 equiv of K₂CO₃ were used in the reaction.

 c 0.5 equiv of Cs₂CO₃ were used in the reaction.

3',5'-Dimethyl-[1,1'-biphenyl]-3-ol



A mixture of PEPPSI-IPr (6.8 mg, 0.010 mmol), Ag₂CO₃ (69.0 mg, 0.25 mmol), K₂CO₃ (25.0 mg, 0.18 mmol), salicylic acid (69.1 mg, 0.50 mmol) and 1-iodo-3,5-dimethylbenzene (218 μ L, 1.5 mmol) in acetic acid (500 μ L) was heated at 150 °C for 16 h. After this time, the reaction mixture was filtered through a plug of Celite® with EtOAc (4 × 5 mL). The filtrate was evaporated to dryness. The crude product was purified by column chromatography (hexanes:EtOAc 90:10) to afford 3',5'-dimethyl-[1,1'-biphenyl]-3-ol (**3aa**) as a light orange oil (80.0 mg, 81%). ¹**H NMR** (400 MHz, CDCl₃) δ 7.29 (t, *J* = 7.9 Hz, 1H), 7.20 (s, 2H), 7.17-7.15 (m, 1H), 7.07-7.05 (m, 1H), 7.01 (s, 1H), 6.80 (ddd, *J* = 8.0, 2.6, 0.9 Hz, 1H), 4.76 (s, 1H), 2.38 (s, 6H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 155.7, 143.3, 140.8, 138.3, 129.9, 129.1, 125.1, 119.9, 114.1, 114.0, 21.4 ppm. These data are consistent with those previously reported.²

4-Fluoro-3',5'-dimethyl-[1,1'-biphenyl]-3-ol



A mixture of PEPPSI-IPr (6.8 mg, 0.010 mmol), Ag₂CO₃ (69.0 mg, 0.25 mmol), K₂CO₃ (25.0 mg, 0.18 mmol), 3-fluoro-2-hydroxybenzoic acid (78.1 mg, 0.50 mmol) and 1-iodo-3,5-dimethylbenzene (218 μ L, 1.5 mmol) in acetic acid (1.0 mL) was heated at 160 °C for 16 h. After this time, the reaction mixture was filtered through a plug of Celite® with EtOAc (4 × 5 mL). The filtrate was evaporated to dryness. The crude product was purified by column chromatography (hexanes:EtOAc 90:10) to afford 4-fluoro-3',5'-dimethyl-[1,1'-biphenyl]-3-ol (**3ab**) as a light orange oil (81.1 mg, 75%). ¹**H NMR** (400 MHz, CDCl₃) δ 7.22 (dd, *J* = 8.5, 2.2 Hz, 1H), 7.15 (s, 2H), 7.14-7.09 (m, 1H), 7.06-7.04 (m, 1H), 6.99 (s, 1H), 5.17 (s, 1H), 2.37 (s, 6H) ppm. ¹³**C NMR** (101 MHz, CDCl₃) δ 150.6 (d, *J* = 237.4 Hz), 143.5 (d, *J* = 14.6 Hz), 140.1, 138.7 (d, *J* = 3.6 Hz), 138.3, 129.1, 125.0, 119.5 (d, *J* = 6.4 Hz), 116.0 (d, *J* = 1.8 Hz), 115.5 (d, *J* = 18.3 Hz), 21.4 ppm. These data are consistent with those previously reported.²

3',4,5'-Trimethyl-[1,1'-biphenyl]-3-ol



A mixture of PEPPSI-IPr (6.8 mg, 0.010 mmol), Ag_2CO_3 (69.0 mg, 0.25 mmol), 2-hydroxy-3methylbenzoic acid (76.1 mg, 0.50 mmol) and 1-iodo-3,5-dimethylbenzene (218 µL, 1.5 mmol) in acetic acid (1.0 mL) was heated at 160 °C for 16 h. After this time, the reaction mixture was filtered through a plug of Celite® with EtOAc (4 × 5 mL). The filtrate was evaporated to dryness. The crude product was purified by column chromatography (hexanes:EtOAc 90:10) to afford 3',4,5'-trimethyl-[1,1'-biphenyl]-3-ol (**3ac**) as an orange oil (75.3 mg, 71%). ¹**H NMR** (400 MHz, CDCl₃) δ 7.18-7.16 (m, 3H), 7.08 (dd, *J* = 7.7, 1.7 Hz, 1H), 7.01-7.00 (m, 1H), 6.98 (s, 1H), 4.69 (s, 1H), 2.37 (s, 6H), 2.29 (s, 3 H) ppm. ¹³**C NMR** (101 MHz, CDCl₃) δ 153.9, 140.8, 140.8, 138.2, 131.2, 128.8, 124.9, 122.5, 119.6, 113.7, 21.4, 15.4 ppm. These data are consistent with those previously reported.²

3',5'-Dimethyl-5-nitro-[1,1'-biphenyl]-3-ol



A mixture of PEPPSI-IPr (6.8 mg, 0.010 mmol), Ag₂CO₃ (69.0 mg, 0.25 mmol), K₂CO₃ (25.0 mg, 0.18 mmol), 2-hydroxy-4-nitrobenzoic acid (91.6 mg, 0.50 mmol) and 1-iodo-3,5-dimethylbenzene (218 µL, 1.5 mmol) in acetic acid (500 µL) was heated at 150 °C for 16 h. After this time, the reaction mixture was filtered through a plug of Celite® with EtOAc (4 × 5 mL). The filtrate was evaporated to dryness. The crude product was purified by column chromatography (hexanes:EtOAc 75:25) to afford 3',5'-dimethyl-5-nitro-[1,1'-biphenyl]-3-ol (**3ad**) as a yellow solid (63.2 mg, 52%). **m. p.** 147-148 °C. **IR**: 3424, 3092, 1591, 1343, 745 cm⁻¹. ¹**H NMR** (400 MHz, CDCl₃) δ 8.03 (dd, *J* = 2.0, 1.6 Hz, 1H), 7.64 (app. t, *J* = 2.2 Hz, 1H), 7.38 (dd, *J* = 2.4, 1.5 Hz, 1H), 7.21 (s, 2H), 7.07(s, 1H), 5.36 (s, 1H), 2.40 (s, 6H) ppm. ¹³C **NMR** (101 MHz, CDCl₃) δ 156.3, 149.5, 144.5, 138.8, 138.4, 130.3, 125.0, 120.3, 114.8, 108.9, 21.4 ppm. **HRMS**: calcd for C₁₄H₁₃NO₃, 243.0895 (M⁺); found, 243.0890.

3',5'-Dimethyl-5-(trifluoromethyl)-[1,1'-biphenyl]-3-ol



A mixture of PEPPSI-IPr (6.8 mg, 0.010 mmol), Ag₂CO₃ (69.0 mg, 0.25 mmol), K₂CO₃ (25.0 mg, 0.18 mmol), 2-hydroxy-4-(trifluoromethyl) benzoic acid (103.1 mg, 0.50 mmol) and 1-iodo-3,5-dimethylbenzene (218 µL, 1.5 mmol) in acetic acid (500 µL) was heated at 150 °C for 16 h. After this time, the reaction mixture was filtered through a plug of Celite® with EtOAc (4 × 5 mL). The filtrate was evaporated to dryness. The crude product was purified by column chromatography (hexanes:EtOAc 90:10) to afford 3',5'-dimethyl-5-(trifluoromethyl)-[1,1'-biphenyl]-3-ol (**3ae**) as a brownish red oil (89.0 mg, 67%). **IR**: 3350, 2918, 1599, 1120, 699 cm⁻¹. ¹**H** NMR (400 MHz, CDCl₃) δ 7.40-7.39 (m, 1H), 7.21-7.20 (m, 1H), 7.18 (s, 2H), 7.04 (s, 2H), 5.08 (s, 1H), 2.39 (s, 6H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 156.0, 144.2, 139.4, 138.6, 132.3 (q, *J* = 32.3 Hz), 129.8, 125.0, 123.9(q, *J* = 272.4 Hz), 117.4, 116.6 (q, *J* = 3.9 Hz), 110.9 (q, *J* = 3.8 Hz), 21.3 ppm. **HRMS**: calcd for C₁₅H₁₃F₃O, 266.0918 (M⁺); found, 266.0913.

5-Fluoro-3',5'-dimethyl-[1,1'-biphenyl]-3-ol



A mixture of PEPPSI-IPr (6.8 mg, 0.010 mmol), Ag₂CO₃ (69.0 mg, 0.25 mmol), K₂CO₃ (25.0 mg, 0.18 mmol), 4-fluoro-2-hydroxybenzoic acid (78.1 mg, 0.50 mmol) and 1-iodo-3,5-dimethylbenzene (218 μ L, 1.5 mmol) in acetic acid (500 μ L) was heated at 150 °C for 16 h. After this time, the reaction mixture was filtered through a plug of Celite® with EtOAc (4 × 5 mL). The filtrate was evaporated to dryness. The crude product was purified by column chromatography (hexanes:EtOAc 90:10) to afford 5-fluoro-3',5'-dimethyl-[1,1'-biphenyl]-3-ol (**3af**) as a brownish orange solid (73.1 mg, 68%). **m. p.** 95-96 °C. IR: 3375, 2917, 1620, 1126, 840 cm⁻¹. ¹**H NMR** (400 MHz, CDCl₃) δ 7.16-7.15 (m, 2H), 7.02-7.01 (m, 1H), 6.87 (ddd, *J* = 9.8, 2.3, 1.5 Hz, 1H), 6.83-6.82 (m, 1H), 6.54 (dt, *J* = 9.8, 2.3 Hz, 1H), 4.90 (s, 1H), 2.37 (s, 6H) ppm. ¹³**C NMR** (101 MHz, CDCl₃) δ 163.8 (d, *J* = 244.9 Hz), 156.8 (d, *J* = 12.0 Hz), 144.6 (d, *J* = 9.8 Hz), 139.7 (d, *J* = 2.6 Hz), 138.4, 129.7, 124.9, 109.9 (d, *J* = 2.7 Hz), 106.7 (d, *J* = 22.3 Hz), 101.8 (d, *J* = 24.9 Hz), 21.36 ppm. **HRMS**: calcd for C₁₄H₁₃FO, 216.0959 (M⁺); found, 216.0945.

5-Chloro-3',5'-dimethyl-[1,1'-biphenyl]-3-ol



A mixture of PEPPSI-IPr (6.8 mg, 0.010 mmol), Ag_2CO_3 (69.0 mg, 0.25 mmol), 4-chloro-2hydroxybenzoic acid (86.3 mg, 0.50 mmol) and 1-iodo-3,5-dimethylbenzene (218 µL, 1.5 mmol) in acetic acid (500 µL) was heated at 160 °C for 16 h. After this time, the reaction mixture was filtered through a plug of Celite® with EtOAc (4 × 5 mL). The filtrate was evaporated to dryness. The crude product was purified by column chromatography (hexanes:EtOAc 90:10) to afford 5-chloro-3',5'dimethyl-[1,1'-biphenyl]-3-ol (**3ag**) as a light orange solid (73.3 mg, 63%). ¹**H NMR** (400 MHz, CDCl₃) δ 7.15-7.14 (m, 3H), 7.02 (s, 1H), 6.93-6.92 (m, 1H), 6.82-6.81 (m, 1H), 4.84 (s, 1H), 2.37 (s, 6H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 156.3, 144.4, 139.5, 138.4, 135.1, 129.7, 124.9, 120.1, 114.4, 112.6, 21.3 ppm. **HRMS**: calcd for C₁₄H₁₃ClO, 232.0655 (M⁺); found, 232.0649. These data are consistent with those previously reported.²

5-Bromo-3',5'-dimethyl-[1,1'-biphenyl]-3-ol



A mixture of PEPPSI-IPr (6.8 mg, 0.010 mmol), Ag₂CO₃ (69.0 mg, 0.25 mmol), K₂CO₃ (25.0 mg, 0.18 mmol), 4-bromo-2-hydroxybenzoic acid (108.5 mg, 0.50 mmol) and 1-iodo-3,5-dimethylbenzene (218 μ L, 1.5 mmol) in acetic acid (500 μ L) was heated at 150 °C for 16 h. After this time, the reaction mixture was filtered through a plug of Celite® with EtOAc (4 × 5 mL). The filtrate was evaporated to dryness. The crude product was purified by column chromatography (hexanes:EtOAc 90:10) to afford 5-bromo-3',5'-dimethyl-[1,1'-biphenyl]-3-ol (**3ah**) as a light yellow solid (92.5 mg, 67%). ¹**H NMR** (400 MHz, CDCl₃) δ 7.30 (app. t, *J* = 1.6 Hz, 1H), 7.15 (s, 2H), 7.02 (s, 1H), 6.97 (app. p, *J* = 2.3 Hz, 2H), 4.83 (s, 1H), 2.37 (s, 6H) ppm. ¹³**C NMR** (101 MHz, CDCl₃) δ 156.4, 144.7, 139.4, 138.4, 129.7, 125.0, 123.0 (CH+C), 117.3, 113.1, 21.4 ppm. These data are consistent with those previously reported.²

3',5,5'-Trimethyl-[1,1'-biphenyl]-3-ol



A mixture of PEPPSI-IPr (6.8 mg, 0.010 mmol), Ag₂CO₃ (69.0 mg, 0.25 mmol), K₂CO₃ (25.0 mg, 0.18 mmol), 2-hydroxy-4-methylbenzoic acid (76.1 mg, 0.50 mmol) and 1-iodo-3,5-dimethylbenzene (218 μ L, 1.5 mmol) in acetic acid (500 μ L) was heated at 150 °C for 16 h. After this time, the reaction mixture was filtered through a plug of Celite® with EtOAc (4 × 5 mL). The filtrate was evaporated to dryness. The crude product was purified by column chromatography (hexanes:EtOAc 90:10) to afford 3',5,5'-trimethyl-[1,1'-biphenyl]-3-ol (**3ai**) as a light orange solid (75.2 mg, 71%). ¹**H NMR** (400 MHz, CDCl₃) δ 7.18 (s, 2H), 6.99-6.97 (m, 2H), 6.85-6.84 (m, 1H), 6.63 (s, 1H), 4.66 (s, 1H), 2.37 (s, 6H), 2.36 (s, 3H) ppm. ¹³**C NMR** (101 MHz, CDCl₃) δ 155.7, 143.1, 140.9, 139.9, 138.2, 129.0, 125.0, 120.8, 114.8, 111.3, 21.44, 21.37 ppm. These data are consistent with those previously reported.²

N-(5-hydroxy-3',5'-dimethyl-[1,1'-biphenyl]-3-yl)acetamide



A mixture of PEPPSI-IPr (6.8 mg, 0.010 mmol), Ag₂CO₃ (69.0 mg, 0.25 mmol), 4-acetamido-2hydroxybenzoic acid (97.6 mg, 0.50 mmol) and 1-iodo-3,5-dimethylbenzene (218 μ L, 1.5 mmol) in acetic acid (500 μ L) was heated at 150 °C for 16 h. After this time, the reaction mixture was filtered through a plug of Celite® with EtOAc (4 × 5 m). The filtrate was evaporated to dryness. The crude product was purified by long column chromatography (hexanes:EtOAc 50:50) to afford *N*-(5-hydroxy-3',5'-dimethyl-[1,1'-biphenyl]-3-yl)acetamido (**3aj**) as a light brown solid (52 mg, 41%). **m. p.** 238-240 °C. **IR**: 3355, 3098, 1746, 1626, 1656, 1592, 1552, 1268, 695 cm⁻¹. ¹**H NMR** (400 MHz, acetone-d₆) δ 9.09 (s, 1H), 8.35 (s, 1H), 7.37 (s, 1H), 7.28 (s, 1H), 7.17 (s, 2H), 6.98 (s, 1H), 6.79-6.78 (m, 1H), 2.33 (s, 6H), 2.09 (s, 3H) ppm. ¹³C NMR (101 MHz, acetone-d₆) δ 168.9, 158.9, 143.7, 141.9, 141.9, 138.9, 129.8, 125.5, 109.9, 109.7, 106.1, 24.4, 21.4 ppm. **HRMS**: calcd for C₁₆H₁₇NO₂, 255.1259 (M⁺); found, 255.1254.

5-Methoxy-3',5'-dimethyl-[1,1'-biphenyl]-3-ol



A mixture of PEPPSI-IPr (6.8 mg, 0.010 mmol), Ag₂CO₃ (69.0 mg, 0.25 mmol), 2-hydroxy-4methoxybenzoic acid (84.1 mg, 0.50 mmol) and 1-iodo-3,5-dimethylbenzene (218 µL, 1.5 mmol) in acetic acid (500 µL) was heated at 150 °C for 16 h. After this time, the reaction mixture was filtered through a plug of Celite® with EtOAc (4 × 5 mL). The filtrate was evaporated to dryness. The crude product was purified by long column chromatography (hexanes:EtOAc 50:50) to afford 5-methoxy-3',5'-dimethyl-[1,1'-biphenyl]-3-ol (**3ak**) as a brownish orange oil (25.0 mg, 22%). ¹**H NMR** (400 MHz, CDCl₃) δ 7.17 (s, 2H), 7.00 (s, 1H), 6.71-6.70 (m, 1H), 6.65-6.64 (m, 1H), 6.39 (app. t, *J* = 2.3 Hz, 1H), 4.83 (s, 1H), 3.84 (s, 3H), 2.37 (s, 6H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 161.1, 156.8, 144.1, 140.8, 138.2, 129.3, 125.0, 106.9, 105.7, 100.3, 55.4, 21.4 ppm. These data are consistent with those previously reported.²

6-Fluoro-3',5'-dimethyl-[1,1'-biphenyl]-3-ol



A mixture of PEPPSI-IPr (6.8 mg, 0.010 mmol), Ag₂CO₃ (69.0 mg, 0.25 mmol), K₂CO₃ (25.0 mg, 0.18 mmol), 5-fluoro-2-hydroxybenzoic acid (78.1 mg, 0.50 mmol) and 1-iodo-3,5-dimethylbenzene (218 μ L, 1.5 mmol) in acetic acid (500 μ L) was heated at 150 °C for 16 h. After this time, the reaction mixture was filtered through a plug of Celite® with EtOAc (4 × 5 mL). The filtrate was evaporated to dryness. The crude product was purified by column chromatography (hexanes:EtOAc 90:10) to afford 6-fluoro-3',5'-dimethyl-[1,1'-biphenyl]-3-ol (**3an**) as an orange solid (58.0 mg, 53%). **m. p.** 53-54 °C. **IR**: 3352, 2916, 1420, 1204, 765 cm⁻¹. ¹**H NMR** (400 MHz, CDCl₃) δ 7.15 (s, 2H), 7.03-6.98 (m, 2H), 6.89-6.86 (m, 1H), 6.76-6.72 (m, 1H), 4.70 (s, 1H), 2.37 (s, 6H) ppm. ¹³C **NMR** (101 MHz, CDCl₃) δ 154.4 (d, *J* = 239.9 Hz), 151.6 (d, *J* = 2.3 Hz), 138.1, 135.6 (d, *J* = 1.4 Hz), 130.3 (d, *J* = 15.5 Hz), 129.7, 126.9 (d, *J* = 2.9 Hz), 117.1 (d, *J* = 3.5 Hz), 116.9 (d, *J* = 25.1 Hz), 115.1 (d, *J* = 8.1 Hz), 21.5 ppm. **HRMS**: calcd for C₁₄H₁₃FO, 216.0950 (M⁺); found, 216.0945.

4'-Nitro-[1,1'-biphenyl]-3-ol



A mixture of PEPPSI-IPr (6.8 mg, 0.010 mmol), Ag₂CO₃ (69.0 mg, 0.25 mmol), K₂CO₃ (25.0 mg, 0.18 mmol), salicylic acid (69.1 mg, 0.50 mmol) and 1-iodo-4-nitrobenzene (374.0 mg, 1.5 mmol) in acetic acid (500 µL) was heated at 150 °C for 16 h. After this time, the reaction mixture was filtered through a plug of Celite® with EtOAc (4 × 5 mL). The filtrate was evaporated to dryness. The crude product was purified by column chromatography (hexanes:EtOAc 75:25) to afford 4'-nitro-[1,1'-biphenyl]-3-ol (**3ba**) as a yellow solid (64.5 mg, 60%). ¹**H NMR** (400 MHz, acetone-d₆) δ 8.61 (s, 1H), 8.36-8.32 (m, 2H), 7.94-7.91 (m, 2H), 7.38 (t, *J* = 7.9 Hz, 1H), 7.27-7.23 (m, 2H), 6.98 (ddd, *J* = 8.1, 2.4, 0.9 Hz, 1H) ppm. ¹³**C NMR** (101 MHz, acetone-d₆) δ 159.0, 148.3, 148.1, 141.0, 131.2, 128.7, 124.8, 119.5, 116.8, 115.0 ppm. These data are consistent with those previously reported.²

4'-(Trifluoromethyl)-[1,1'-biphenyl]-3-ol



A mixture of PEPPSI-IPr (6.8 mg, 0.010 mmol), Ag₂CO₃ (69.0 mg, 0.25 mmol), K₂CO₃ (25 mg, 0.18 mmol), salicylic acid (69.1 mg, 0.50 mmol), 4-iodobenzotrifluoride (220 µL, 1.5 mmol) in acetic acid (500 µL) was heated at 150 °C for 16 h. After this time, the reaction mixture was filtered through a plug of Celite® with EtOAc (4 × 5 mL). The filtrate was evaporated to dryness. The crude product was purified by column chromatography (hexanes:EtOAc 90:10) to afford 4'-(trifluoromethyl)-[1,1'-biphenyl]-3-ol (**3ca**) as a pale yellow solid (79.5 mg, 67%). **m. p**. 73-75 °C. **IR**: 3261, 1573, 1322, 840 cm⁻¹. ¹**H NMR** (400 MHz, CDCl₃) δ 7.73-7.68 (m, 4H), 7.37 (t, *J* = 7.9 Hz, 1H), 7.21 (ddd, *J* = 7.7, 1.6, 0.9 Hz, 1H), 7.11-7.10 (m, 1H), 6.91 (ddd, *J* = 8.1, 2.5, 0.9 Hz, 1H), 4.91 (s, 1H) ppm. ¹³**C NMR** (101 MHz, CDCl₃) δ 156.0, 144.2, 141.6, 130.3, 129.6 (q, *J* = 32.5 Hz), 124.3 (q, *J* = 272.0 Hz), 127.4, 125.7 (q, *J* = 3.8 Hz), 119.9, 115.1, 114.3 ppm. **HRMS**: calcd for C₁₃H₉F₃O, 238.0605 (M⁺); found, 238.0600.

4'-Fluoro-[1,1'-biphenyl]-3-ol



A mixture of PEPPSI-IPr (6.8 mg, 0.010 mmol), Ag₂CO₃ (69.0 mg, 0.25 mmol), K₂CO₃ (25.0 mg, 0.18 mmol), salicylic acid (69.1 mg, 0.50 mmol), 1-fluoro-4-iodobenzene (173 µL, 1.5 mmol) in acetic acid (500 µL) was heated at 150 °C for 16 h. After this time, the reaction mixture was filtered through a plug of Celite® with EtOAc (4 × 5 mL). The filtrate was evaporated to dryness. The crude product was purified by column chromatography (hexanes:EtOAc 90:10) to afford 4'-fluoro-[1,1'-biphenyl]-3-ol (**3da**) as an off white solid (64.9 mg, 69%). ¹H NMR (400 MHz, CDCl₃) δ 7.56-7.50 (m, 2H), 7.30 (t, *J* = 7.9 Hz, 1H), 7.15-7.09 (m, 3H), 7.02-7.01 (m, 1H), 6.82 (ddd, *J* = 8.1, 2.5, 0.9 Hz, 1H), 4.83 (bs, 1H)

ppm. ¹³C NMR (101 MHz, CDCl₃) δ 162.6 (d, J = 246.6 Hz), 155.9, 142.1, 136.9 (d, J = 3.2 Hz), 130.1, 128.7, 128.6, 119.7, 115.6 (d, J = 21.4 Hz), 114.1 (d, J = 18.4 Hz) ppm. These data are consistent with those previously reported.²

4'-Chloro-[1,1'-biphenyl]-3-ol

A mixture of PEPPSI-IPr (6.8 mg, 0.010 mmol), Ag₂CO₃ (69.0 mg, 0.25 mmol), K₂CO₃ (25.0 mg, 0.18 mmol), salicylic acid (69.1 mg, 0.50 mmol), 1-chloro-4-iodobenzene (358 mg, 1.5 mmol) in acetic acid (500 µL) was heated at 150 °C for 16 h. After this time, the reaction mixture was filtered through a plug of Celite® with EtOAc (4 × 5 mL). The filtrate was evaporated to dryness. The crude product was purified by column chromatography (hexanes:EtOAc 90:10) to afford 4'-chloro-[1,1'-biphenyl]-3-ol (**3ea**) as a light orange solid (69.5 mg, 68%). ¹H NMR (400 MHz, CDCl₃) δ 7.51-7.48 (m, 2H), 7.41-7.38 (m, 2H), 7.31 (t, *J* = 7.9 Hz, 1H), 7.13 (ddd, *J* = 7.7, 1.6, 0.9 Hz, 1H), 7.03-7.02 (m, 1H), 6.83 (ddd, *J* = 8.1, 2.5, 0.9 Hz, 1H), 4.85 (s, 1H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 156.0, 141.8, 139.2, 133.6, 130.1, 128.9, 128.4, 119.6, 114.5, 114.0 ppm. These data are consistent with those previously reported.²

4'-Bromo-[1,1'-biphenyl]-3-ol



A mixture of PEPPSI-IPr (6.8 mg, 0.010 mmol), Ag₂CO₃ (69.0 mg, 0.25 mmol), K₂CO₃ (25.0 mg, 0.18 mmol), salicylic acid (69.1 mg, 0.50 mmol), 1-bromo-4-iodobenzene (424 mg, 1.5 mmol) in acetic acid (500 µL) was heated at 150 °C for 16 h. After this time, the reaction mixture was filtered through a plug of Celite® with EtOAc (4 × 5 mL). The filtrate was evaporated to dryness. The crude product was purified by column chromatography (hexanes:EtOAc 90:10) to afford 4'-bromo-[1,1'-biphenyl]-3-ol (**3fa**) as a light orange solid (74.7 mg, 60%). ¹**H NMR** (400 MHz, CDCl₃) δ 7.58-7.54 (m, 2H), 7.45-7.42 (m, 2H), 7.31 (t, *J* = 7.9 Hz, 1H), 7.13 (ddd, *J* = 7.7, 1.6, 0.9 Hz, 1H), 7.03-7.02 (m, 1H), 6.83 (ddd, *J* = 8.1, 2.5, 0.9 Hz, 1H), 4.79 (s, 1H) ppm. ¹³**C NMR** (101 MHz, CDCl₃) δ 156.1, 141.9, 139.8, 132.0, 130.3, 128.8, 121.9, 119.7, 114.7, 114.1 ppm. These data are consistent with those previously reported.²

4'-Iodo-[1,1'-biphenyl]-3-ol



A mixture of PEPPSI-IPr (6.8 mg, 0.010 mmol), Ag_2CO_3 (69.0 mg, 0.25 mmol), K_2CO_3 (25.0 mg, 0.18 mmol), salicylic acid (69.1 mg, 0.50 mmol), 1,4-diiodobenzene (495 mg, 1.5 mmol) in acetic acid (500

µL) was heated at 150 °C for 16 h. After this time, the reaction mixture was filtered through a plug of Celite® with EtOAc (4 × 5 mL). The filtrate was evaporated to dryness. The crude product was purified by column chromatography (hexanes:EtOAc 90:10) to afford 4'-iodo-[1,1'-biphenyl]-3-ol (**3ga**) as an orange solid (59.2 mg, 40%). **m. p.** 123-126 °C. **IR:** 3335, 1593, 1445, 1388, 1194, 1002, 878, 823, 780, 688 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 7.75 (d, J = 8.4 Hz, 2H), 7.33-7.29 (m, 3H), 7.12 (d, J = 7.8 Hz, 1H), 7.02-7.01 (m, 1H), 6.83 (dd, J = 8.0, 2.5 Hz, 1H), 4.84 (s, 1H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 155.9, 141.9, 140.2, 137.9, 130.2, 129.0, 119.6, 114.6, 113.8, 93.3 ppm. **HRMS**: calcd for C₁₂H₁₀IO, 296.9698 (M+H⁺); found, 296.9771.

4'-Methoxy-[1,1'-biphenyl]-3-ol



A mixture of PEPPSI-IPr (6.8 mg, 0.010 mmol), Ag₂CO₃ (69.0 mg, 0.25 mmol), K₂CO₃ (35.0 mg, 0.25 mmol), salicylic acid (69.1 mg, 0.50 mmol), 1-iodo-4-methoxybenzene (39.1 mg, 0.167 mmol) in acetic acid (500 µL) was heated at 130 °C for 16 h. After this time, the reaction mixture was filtered through a plug of Celite® with EtOAc (4 × 5 mL). The filtrate was evaporated to dryness. The crude product was purified by column chromatography (hexanes:EtOAc 90:10) to afford 4'-methoxy-[1,1'-biphenyl]-3-ol (**3ha**) as an off white solid (27.7 mg, 83%). ¹**H** NMR (400 MHz, CDCl₃) δ 7.53-7.49 (m, 2H), 7.28 (t, *J* = 8.0 Hz, 1H), 7.13 (ddd, *J* = 7.7, 1.6, 1.0 Hz, 1H), 7.03-7.02 (m, 1H), 6.99-6.95 (m, 2H), 6.78 (ddd, *J* = 8.0, 2.5, 0.9 Hz, 1H), 4.78 (s, 1H), 3.85 (s, 3H) ppm. ¹³**C** NMR (101 MHz, CDCl₃) δ 159.3, 155.8, 142.6, 133.3, 129.9, 128.1, 119.4, 114.2, 113.7, 113.6, 55.4 ppm. These data are consistent with those previously reported.²

3'-Hydroxy-[1,1'-biphenyl]-4-carbaldehyde



A mixture of PEPPSI-IPr (6.8 mg, 0.010 mmol), Ag₂CO₃ (69.0 mg, 0.25 mmol), K₂CO₃ (35.0 mg, 0.25 mmol), salicylic acid (69.1 mg, 0.50 mmol), 4-iodobenzaldehyde (38.7 mg, 0.167 mmol) in acetic acid (500 µL) was heated at 130 °C for 16 h. After this time, the reaction mixture was filtered through a plug of Celite® with EtOAc (4 × 5 mL). The filtrate was evaporated to dryness. The crude product was purified by column chromatography (hexanes:EtOAc 80:20) to afford 3'-hydroxy-[1,1'-biphenyl]-4-carbaldehyde (**3ia**) as a white solid (28.2 mg, 85%). ¹**H NMR** (400 MHz, acetone-d₆) δ 10.09 (s, 1H), 8.56 (s, 1H), 8.01-7.99 (m, 2H), 7.86-7.84 (m, 2H), 7.34 (app. t, *J* = 7.7 Hz, 1H), 7.23-7.19 (m, 2H), 6.94-6.91 (m, 1H) ppm. ¹³C NMR (101 MHz, acetone-d₆) δ 192.5, 158.9, 147.6, 142.0, 136.6, 131.1, 130.9, 128.4, 119.4, 116.4, 115.0 ppm. These data are consistent with those previously reported.² (**3'-Hydroxy-[1,1'-biphenyl]-4-yl)mEtOAc**



A mixture of PEPPSI-IPr (6.8 mg, 0.010 mmol), Ag₂CO₃ (69.0 mg, 0.25 mmol), K₂CO₃ (35.0 mg, 0.25 mmol), salicylic acid (69.1 mg, 0.50 mmol), 4-iodobenzyl alcohol (39.1 mg, 0.167 mmol) in acetic acid (500 µL) was heated at 130 °C for 16 h. After this time, the reaction mixture was filtered through a plug of Celite® with EtOAc (4 × 5 mL). The filtrate was evaporated to dryness. The crude product was purified by column chromatography (hexanes:EtOAc 75:25) to afford 3'-hydroxy-[1,1'-biphenyl]-4-carbaldehyde (**3ja**) as an off white solid (32.3 mg, 80%). ¹**H NMR** (400 MHz, CDCl₃) δ 7.58-7.55 (m, 2H), 7.43-7.41 (m, 2H), 7.31 (t, *J* = 7.9 Hz, 1H), 7.16-7.14 (m, 1H), 7.07-7.06 (m, 1H), 6.83 (ddd, *J* = 8.1, 2.5, 0.9 Hz, 1H), 5.26 (s, 1H), 5.15 (s, 2H), 2.13 (s, 3H) ppm. ¹³**C NMR** (101 MHz, CDCl₃) δ 171.2, 156.0, 142.4, 140.9, 135.1, 130.0, 128.8, 127.3, 119.7, 114.4, 114.1, 66.1, 21.1 ppm. These data are consistent with those previously reported.²

3',5'-Dinitro-[1,1'-biphenyl]-3-ol



A mixture of PEPPSI-IPr (6.8 mg, 0.010 mmol), Ag₂CO₃ (69.0 mg, 0.25 mmol), K₂CO₃ (25.0 mg, 0.18 mmol), salicylic acid (69.1 mg, 0.50 mmol), 1-Iodo-3,5-dinitrobenzene (441 mg, 1.5 mmol) in acetic acid (500 µL) was heated at 150 °C for 16 h. After this time, the reaction mixture was filtered through a plug of Celite® with EtOAc (4 × 5 mL). The filtrate was evaporated to dryness. The crude product was purified by column chromatography (hexanes:EtOAc 50:50) to afford 3',5'-dinitro-[1,1'-biphenyl]-3-ol (**3ka**) as a yellow solid (82.1 mg, 63%). **m. p**. 208-210 °C. **IR**: 3440, 3076, 1522, 1336, 727 cm⁻¹. ¹**H NMR** (400 MHz, acetone-d₆) δ 8.93 (t, *J* = 2.1 Hz, 1H), 8.84 (d, *J* = 2.1 Hz, 2H), 8.70 (s, 1H), 7.44 (t, *J* = 7.8 Hz, 1H), 7.38 (ddd, *J* = 7.7, 1.7, 1.1 Hz, 1H), 7.34 (t, *J* = 2.0 Hz, 1H), 7.04 (ddd, *J* = 8.0, 2.4, 1.1 Hz, 1H) ppm. ¹³C **NMR** (101 MHz, acetone-d₆) δ 159.2, 150.0, 145.2, 138.9, 131.6, 127.6, 119.4, 117.8, 117.5, 115.0 ppm. HRMS: calcd for C₁₂H₈N₂O₅, 260.0433 (M⁺); found, 260.0428.

3',5'-Bis(trifluoromethyl)-[1,1'-biphenyl]-3-ol



A mixture of PEPPSI-IPr (6.8 mg, 0.010 mmol), Ag_2CO_3 (69.0 mg, 0.25 mmol), K_2CO_3 (25.0 mg, 0.18 mmol), salicylic acid (69.1 mg, 0.50 mmol), 1-Iodo-3,5-bis(trifluoromethyl)benzene (266 µL, 1.5 mmol) in acetic acid (500 µL) was heated at 150 °C for 16 h. After this time, the reaction mixture was filtered through a plug of Celite® with EtOAc (4 × 5 mL). The filtrate was evaporated to dryness. The

crude product was purified by column chromatography (hexanes:EtOAc 85:15) to afford 3',5'bis(trifluoromethyl)-[1,1'-biphenyl]-3-ol (**3la**) as a white solid (97.0 mg, 63%). **m. p.** 93-94 °C. **IR**: 3296, 1378, 701 cm⁻¹. ¹**H NMR** (400 MHz, CDCl₃) δ 7.99 (s, 2H), 7.86 (s, 1H), 7.38 (t, J = 7.9 Hz, 1H), 7.18 (ddd, J = 7.7, 1.6, 0.9 Hz, 1H), 7.08 (t, J = 2.4 Hz, 1H), 6.92 (ddd, J = 8.1, 2.5, 0.8 Hz, 1H), 4.96 (s, 1H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 156.2, 142.8, 140.0, 132.1 (q, J = 33.2 Hz), 130.6, 127.2 (d, J = 2.7 Hz), 123.4 (q, J = 272.7 Hz), 121.1 (dt, J = 7.8, 3.8 Hz), 119.8, 115.8, 114.2 ppm. **HRMS**: calcd for C₁₄H₈F₆O, 306.0479 (M⁺); found, 306.0474.

3'-(Trifluoromethyl)-[1,1'-biphenyl]-3-ol



A mixture of PEPPSI-IPr (6.8 mg, 0.010 mmol), Ag₂CO₃ (69.0 mg, 0.25 mmol), K₂CO₃ (25.0 mg, 0.18 mmol), salicylic acid (69.1 mg, 0.50 mmol), 3-iodobenzotrifluoride (216 µL, 1.5 mmol) in acetic acid (500 µL) was heated at 150 °C for 16 h. After this time, the reaction mixture was filtered through a plug of Celite® with EtOAc (4 × 5 mL). The filtrate was evaporated to dryness. The crude product was purified by column chromatography (hexanes:EtOAc 90:10) to afford 3'-(trifluoromethyl)-[1,1'-biphenyl]-3-ol (**3ma**) as an off white solid (80.9 mg, 68%). ¹**H** NMR (400 MHz, CDCl₃) δ 7.81 (s, 1H), 7.75-7.73 (m, 1H), 7.62-7.53 (m, 2H), 7.34 (t, *J* = 7.9 Hz, 1H), 7.17 (ddd, *J* = 7.7, 1.6, 0.9 Hz, 1H), 7.08-7.07 (m, 1H), 6.87 (ddd, *J* = 8.1, 2.5, 0.9 Hz, 1H), 4.85 (s, 1H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 156.0, 141.5, 131.2 (q, *J* = 32.2 Hz), 130.4, 130.4, 130.3, 129.2, 124.2 (q, *J* = 272.4 Hz), 124.2 (q, *J* = 3.8 Hz), 123.9 (q, *J* = 3.8 Hz), 119.8, 115.0, 114.2 ppm. These data are consistent with those previously reported.²

1-(3'-Hydroxy-[1,1'-biphenyl]-3-yl)ethanone



A mixture of PEPPSI-IPr (6.8 mg, 0.010 mmol), Ag₂CO₃ (69.0 mg, 0.25 mmol), K₂CO₃ (35.0 mg, 0.25 mmol), salicylic acid (69.1 mg, 0.50 mmol), 3'-iodoacetophenone (41.0 mg, 0.167 mmol) in acetic acid (500 µL) was heated at 130 °C for 16 h. After this time, the reaction mixture was filtered through a plug of Celite® with EtOAc (4 × 5 mL). The filtrate was evaporated to dryness. The crude product was purified by column chromatography (hexanes:EtOAc 80:20) to afford1-(3'-hydroxy-[1,1'-biphenyl]-3-yl)ethanone (**3na**) as a light orange oil (27.3 mg, 77%). ¹**H NMR** (400 MHz, CDCl₃) δ 8.17 (app. t, *J* = 1.6 Hz, 1H), 7.93 (ddd, *J* = 7.7, 1.7, 1.2 Hz, 1H), 7.77 (ddd, *J* = 7.7, 1.9, 1.1 Hz, 1H), 7.53 (t, *J* = 7.7 Hz, 1H), 7.33 (t, *J* = 7.9 Hz, 1H), 7.18 (ddd, *J* = 7.7, 1.6, 1.0 Hz, 1H), 7.12-7.11 (m, 1H), 6.88 (ddd, *J* = 8.1, 2.5, 0.9 Hz, 1H), 5.34 (s, 1H), 2.66 (s, 3H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 198.5, 156.2, 141.9, 141.3, 137.6, 131.8, 130.2, 129.1, 127.5, 126.9, 119.7, 114.8, 114.2, 26.8 ppm. These data are consistent with those previously reported.²

3'-Methyl-[1,1'-biphenyl]-3-ol



A mixture of PEPPSI-IPr (6.8 mg, 0.010 mmol), Ag₂CO₃ (69.0 mg, 0.25 mmol), K₂CO₃ (35 mg, 0.25 mmol), salicylic acid (69.1 mg, 0.50 mmol), 3-Iodotoluene (193 µL, 1.5 mmol) in acetic acid (500 µL) was heated at 150 °C for 16 h. After this time, the reaction mixture was filtered through a plug of Celite® with EtOAc (4 × 5 mL). The filtrate was evaporated to dryness. The crude product was purified by column chromatography (hexanes:EtOAc 90:10) to afford 3'-methyl-[1,1'-biphenyl]-3-ol (**30a**) as an orange oil (50.6 mg, 55%). ¹H NMR (400 MHz, CDCl₃) δ 7.40-7.28 (m, 4H), 7.18-7.16 (m, 2H), 7.07-7.06 (m, 1H), 6.82 (ddd, *J* = 8.0, 2.6, 0.9 Hz, 1H), 4.84 (s, 1H), 2.42 (s, 3H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 155.8, 143.2, 140.7, 138.4, 129.9, 128.7, 128.3, 127.9, 124.2, 119.8, 114.1, 114.1, 21.5 ppm. These data are consistent with those previously reported.²

2'-Fluoro-[1,1'-biphenyl]-3-ol



A mixture of PEPPSI-IPr (6.8 mg, 0.010 mmol), Ag₂CO₃ (69.0 mg, 0.25 mmol), K₂CO₃ (25.0 mg, 0.18 mmol), salicylic acid (69.1 mg, 0.50 mmol), 2-fluoroiodobenzene (175 µL, 1.5 mmol) in acetic acid (500 µL) was heated at 150 °C for 16 h. After this time, the reaction mixture was filtered through a plug of Celite® with EtOAc (4 × 5 mL). The filtrate was evaporated to dryness. The crude product was purified by column chromatography (hexanes:EtOAc 90:10) to afford 2'-fluoro-[1,1'-biphenyl]-3-ol (**3qa**) as a light brown solid (23.0 mg, 24%). **m. p.** 99-101 °C. **IR**: 3222, 2926, 1571, 1584, 1180, 759 cm⁻¹. ¹**H NMR** (400 MHz, CDCl₃) δ 7.43 (td, *J* = 7.7, 1.8 Hz, 1H), 7.34-7.29 (m, 2H), 7.22-7.12 (m, 3H), 7.05-7.03 (m, 1H), 6.85 (ddd, *J* = 8.1, 2.6, 0.9 Hz, 1H), 4.78 (s, 1H) ppm. ¹³**C NMR** (101 MHz, CDCl₃) δ 159.7 (d, *J* = 248.0 Hz), 155.5, 137.4, 130.7 (d, *J* = 3.4 Hz), 129.7, 129.1 (d, *J* = 8.3 Hz), 128.6 (d, *J* = 13.3 Hz), 124.3 (d, *J* = 3.7 Hz), 121.6 (d, *J* = 2.8 Hz), 116.2 (d, *J* = 17.6 Hz), 116.0 (d, *J* = 2.0 Hz), 114.7 ppm. **HRMS**: calcd for C₁₂H₉FO, 188.0637 (M⁺); found, 188.0632.

3-(1-Tosyl-1H-indol-5-yl)phenol



A mixture of PEPPSI-IPr (6.8 mg, 0.010 mmol), Ag_2CO_3 (69.0 mg, 0.25 mmol), K_2CO_3 (25.0 mg, 0.18 mmol), salicylic acid (69.1 mg, 0.50 mmol), 5-iodo-1-tosyl-1H-indole (596 mg, 1.5 mmol) in acetic acid (500 µL) was heated at 150 °C for 16 h. After this time, the reaction mixture was filtered through a plug of Celite® with EtOAc (4 × 5 mL). The filtrate was evaporated to dryness. The crude product was purified by column chromatography (hexanes:EtOAc 70:30) to afford 3-(1-tosyl-1*H*-indol-5-yl)phenol (**3ra**) as a brown solid (54.5 mg, 30%). ¹**H NMR** (400 MHz, CDCl₃) δ 8.02 (d, *J* = 8.6 Hz, 1H), 7.81-

7.78 (m, 2H), 7.70-7.69 (m, 1H), 7.58 (d, J = 3.7 Hz, 1H), 7.51 (dd, J = 8.6, 1.8 Hz, 1H), 7.29 (t, J = 7.9 Hz, 1H), 7.24-7.22 (m, 2H), 7.16-7.14 (m, 1H), 7.07-7.05 (m, 1H), 6.80 (ddd, J = 8.1, 2.5, 0.9 Hz, 1H), 6.69 (dd, J = 3.7, 0.7 Hz, 1H), 4.91 (s, 1H), 2.34 (s, 3H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 155.9, 145.1, 143.1, 136.3, 135.3, 134.3, 131.3, 130.0, 130.0, 127.0, 126.9, 124.1, 120.0, 119.8, 114.3, 114.0, 113.7, 109.3, 21.6 ppm. These data are consistent with those previously reported.²

3-(2,6-Dichloropyridin-4-yl)phenol



A mixture of PEPPSI-IPr (6.8 mg, 0.010 mmol), Ag₂CO₃ (69.0 mg, 0.25 mmol), K₂CO₃ (25.0 mg, 0.18 mmol), salicylic acid (69.1 mg, 0.50 mmol), 2,6-dichloro-4-iodopyridine (409 µL, 1.5 mmol) in acetic acid (500 µL) was heated at 150 °C for 16 h. After this time, the reaction mixture was filtered through a plug of Celite® with EtOAc (4 × 5 mL). The filtrate was evaporated to dryness. The crude product was purified by column chromatography (hexanes:EtOAc 85:15) to afford 3-(2,6-dichloropyridin-4-yl)phenol (**3sa**) as a pale yellow solid (84.0 mg, 70%). ¹**H NMR** (400 MHz, CDCl₃) δ 7.45 (s, 2H), 7.37 (t, *J* = 7.9 Hz, 1H), 7.17-7.15 (m, 1H), 7.06-7.05 (m, 1H), 6.95 (ddd, *J* = 8.1, 2.5, 0.9 Hz, 1H) 5.01 (bs, 1H) ppm. ¹³**C NMR** (101 MHz, CDCl₃) δ 156.4, 153.7, 151.1, 137.4, 130.7, 120.9, 119.5, 117.3, 114.1 ppm. These data are consistent with those previously reported.²

Derivatization of product 3ai

Procedure to prepare 2-((3',5'-dimethyl-[1,1'-biphenyl]-3-yl)methyl)-5-nitropyridine (4a).³



NaH (11 mg, 0.275 mmol, 60% in mineral oil) was slowly added to a solution of biaryl **3ai** (53.1 mg, 0.25 mmol) in DMF (0.5 mL), at 0 °C. After stirring for 30 min, 2-chloro-5-nitro-pyridine (40.0 mg, 0.25 mmol) was added, and the resulting mixture was stirred at room temperature for 16 h. After that time, the crude mixture was filtered through a plug of Celite® with EtOAc (4×5 mL), the filtrate was evaporated to dryness, and the crude product was purified by column chromatography (hexanes:EtOAc 85:15) to afford 2-((3',5'-dimethyl-[1,1'-biphenyl]-3-yl)methyl)-5-nitropyridine (**4a**) as a pale brownish solid (81.0 mg, 97%). **m. p.** 93-95 °C. **IR**: 2916, 1569, 1347, 1300, 1259, 842, 684 cm⁻¹. ¹**H NMR** (400 MHz, CDCl₃) δ 9.07 (d, J = 2.8 Hz, 1H), 8.47 (dd, J = 9.1, 2.8 Hz, 1H), 7.33 (s, 1H), 7.19 (s, 2H), 7.16 (s, 1H), 7.04 (d, J = 9.1 Hz, 1H), 7.00 (s, 1H), 6.94 (s, 1H), 2.45 (s, 3H), 2.37 (s, 6H) ppm. ¹³C **NMR** (101 MHz, CDCl₃) δ 167.1, 153.1, 145.2, 143.4, 140.4, 140.3, 140.2, 138.4, 134.9, 129.4, 125.7, 125.1, 120.5, 117.3, 111.2, 21.6, 21.4 ppm. **HRMS**: calcd for C₂₀H₁₉N₂O₃, 335.1317 (M+H⁺); found, 335.1390.

Procedure to prepare 3-methoxy-3',5,5'-trimethyl-1,1'-biphenyl (4b).⁴



K₂CO₃ (32 mg, 0.23 mmol) was added to a solution of biaryl **3ai** (21.2 mg, 0.10 mmol) in acetone (0.5 mL). After stirring for 1 min, MeI (14 μL, 0.23 mmol) was added and the resulting mixture was stirred at room temperature for 16 h. After that time, the mixture was filtered through a small plug of silica with EtOAc (4 × 5 mL), the filtrate was evaporated to dryness, and the crude product was purified by column chromatography (hexanes) to afford 3-methoxy-3',5,5'-trimethyl-1,1'-biphenyl (**4b**) as a colorless oil (21.7 mg, 96%). **IR**: 2918, 1590, 1461, 1262, 1152, 1064, 836, 694 cm⁻¹. ¹**H NMR** (400 MHz, CDCl₃) δ 7.20 (s, 2H), 7.00 (s, 2H), 6.93 (s, 1H), 6.72 (s, 1H), 3.86 (s, 3H), 2.40 (s, 3H), 2.39 (s, 6H) ppm. ¹³**C NMR** (101 MHz, CDCl₃) δ 159.9, 142.9, 141.3, 139.6, 138.2, 129.0, 125.1, 120.7, 113.5, 109.9, 55.3, 21.7, 21.4 ppm. **HRMS**: calcd for C₁₆H₁₉O, 227.1358 (M+H⁺); found, 227.1430.

Procedure to prepare 3',5,5'-trimethyl-[1,1'-biphenyl]-3-yl trifluoromethanesulfonate (4f).⁵



A solution of trifluoromethanesulfonic anhydride (245 µL, 1.44 mmol) in DCM (0.6 mL) was added dropwise to a solution of pyridine (195 µL, 2.4 mmol) and **3ai** (254 mg, 1.2 mmol) in anhydrous DCM into an ice bath. After complete addition, the mixture was warmed to room temperature and allowed to stir for 1 h. The mixture was then filtered through a small plug of silica with EtOAc (4 × 5 mL), the filtrate was evaporated to dryness, the crude product was purified by column chromatography (hexanes) to afford 3',5,5'-trimethyl-[1,1'-biphenyl]-3-yl trifluoromethanesulfonate (**4f**) as a colorless oil (397 mg, 96%). **IR**: 2924, 1584, 1422, 1206, 1141, 959, 828, 691, 609 cm⁻¹. ¹**H NMR** (400 MHz, CDCl₃) δ 7.40 (s, 1H), 7.26 (s, 1H), 7.16 (s, 2H), 7.05 (s, 2H), 2.46 (s, 3H), 2.39 (s, 6H) ppm. ¹³**C NMR** (101 MHz, CDCl₃) δ 149.9, 143.9, 140.9, 139.3, 138.6, 129.8, 127.9, 125.1, 120.1, 118.8 (d, *J* = 320.7 Hz), 117.0, 21.5, 21.4 ppm. **HRMS**: calcd for C₁₆H₁₆F₃NO₃S, 362.1038 (M+NH₄⁺); found, 362.1032.

Procedure to prepare 3',5,5'-trimethyl-N-phenyl-[1,1'-biphenyl]-3-amine (4c).⁶



A flame-dried vial was charged with $Pd(OAc)_2$ (1.1 mg, 0.005 mmol), BINAP (5.0 mg, 0.008 mmol), Cs_2CO_3 (45.6 mg, 1.4 equiv) and **4f** (34.4 mg, 0.1 mmol) in PhMe (0.1 M). Aniline (11 µL, 0.12 mmol) was added at room temperature under an argon atmosphere. The reaction mixture was allowed to stir at 120 °C for 16 h. The mixture was then filtered through a small plug of silica with EtOAc (4 × 5 mL), the filtrate was evaporated to dryness, the crude product was purified by column chromatography (hexanes:EtOAc 85:15) to afford 3',5,5'-trimethyl-*N*-phenyl-[1,1'-biphenyl]-3-amine (**4c**) as a brown oil (27.6 mg, 96%). **IR**: 3394, 2916, 1586, 1494, 1348, 1235, 1030, 837, 741, 691 cm⁻¹. ¹**H NMR** (400 MHz, CDCl₃) δ 7.30-7.26 (m, 2H), 7.18 (s, 2H), 7.12-7.10 (m, 3H), 6.99-6.98 (m, 2H), 6.96-6.92 (m, 1H), 6.88 (s, 1H), 5.72 (s, 1H), 2.37 (s, 9H) ppm. ¹³**C NMR** (101 MHz, CDCl₃) δ 143.4, 143.3, 142.7, 141.3, 139.5, 138.2, 129.4, 128.9, 125.1, 121.1, 120.9, 117.9, 117.4, 114.0, 21.6, 21.4 ppm. **HRMS**: calcd for C₂₁H₂₂N, 288.1674 (M+H⁺); found, 288.1747.

Procedure to prepare 3,5,5'-trimethyl-1,1':3',1''-terphenyl (4d).⁷



A solution of Na₂CO₃ (21.2 mg, 0.2 mmol) in degased H₂O (1.0 mL) was added to a mixture of Pd(PPh₃)₄ (0.6 mg, 0.0005 mmol), **4f** (34.4 mg, 0.1 mmol) and phenylboronic acid (13.7 mg, 0.112 mmol) in degased monolyme (1.0 mL), under an argon atmosphere. The reaction mixture was stirred at 95 °C for 2.5 h. The mixture was then filtered through a small plug of silica with EtOAc (4 × 5 mL), the filtrate was evaporated to dryness, the crude product was purified by column chromatography (hexanes) to afford 3,5,5'-trimethyl-1,1':3',1"-terphenyl (**4d**) as a colourless oil (26.3 mg, 97%). **IR**: 3030, 2917, 1560, 1459, 1032, 844, 761, 697 cm⁻¹. ¹**H NMR** (400 MHz, CDCl₃) δ 7.65-7.63 (m, 2H), 7.59 (s, 1H), 7.47-7.43 (m, 2H), 7.38-7.33 (m, 3H), 7.26-7.25 (m, 2H), 7.01 (s, 1H), 2.48 (s, 3H), 2.39 (s, 6H) ppm. ¹³**C NMR** (101 MHz, CDCl₃) δ 142.1, 141.7, 141.5, 141.4, 138.7, 138.3, 129.0, 128.8, 127.3, 127.0, 126.9, 125.2, 123.5, 21.6, 21.5 ppm. **HRMS**: calcd for C₂₁H₂₁, 273.1565 (M+H⁺); found, 273.1638.

Procedure to prepare 3',5,5'-trimethyl-[1,1'-biphenyl]-3-yl 4-methylbenzenesulfonate (4g).



Et₃N (31 µL, 0.22 mmol) was slowly added to a solution of **3ai** (42.4 mg, 0.2 mmol) and ptoluenesulfonyl chloride (41.9 mg, 0.22 mmol) in MeCN (1 mL). The reaction mixture was allowed to stir at room temperature for 1 h. The mixture was then filtered through a small plug of silica with EtOAc (4 \times 5 mL), the filtrate was evaporated to dryness, and the crude product was purified by chromatography (hexanes) to afford 3',5,5'-trimethyl-[1,1'-biphenyl]-3-yl column 4methylbenzenesulfonate (4g) as a colourless oil (69.5 mg, 95%). IR: 1598, 1358, 1189, 1178, 965, 862, 847, 790, 671 cm⁻¹. ¹**H NMR** (400 MHz, CDCl₃) δ 7.76 (d, J = 8.3 Hz, 2H), 7.34 (d, J = 8.0 Hz, 2H), 7.25 (s, 1H), 7.00 (s, 2H), 6.98 (s, 1H), 6.87 (s, 1H), 6.84 (s, 1H), 2.47 (s, 3H), 2.35 (s, 9H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 149.9, 145.2, 142.8, 140.0, 139.8, 138.3, 132.7, 129.7, 129.4, 128.7, 126.6, 125.0, 121.6, 118.0, 21.7, 21.40, 21.35 ppm. **HRMS**: calcd for $C_{22}H_{26}NO_3S$, 384.1628 (M+NH₄⁺); found, 384.1628.

Procedure to prepare 3',5,5'-trimethyl-[1,1'-biphenyl]-3-carbonitrile (4e).⁸



Et₃N (0.1 μL) was added to a mixture of Pd(OAc)₂ (0.45 mg, 0.002 mmol) and CM-Phos (3.2 mg, 0.008 mmol) in degased anhydrous DCM (0.5 mL), under an argon atmosphere. The resulting mixture was very gently heated with a heat gun with constant stirring for 5 min. The solvent was then removed under vacuum. **4g** (34.4 mg, 0.1 mmol), K₂CO₃ (1.7 mg, 0.0125 mmol) and K₄[Fe(CN)₆]·H₂O (21.1 mg, 0.05 mmol) were charged successively to the tube, and degased ^tBuOH (0.25 mL) and H₂O (0.25 mL) were added as solvent. The reaction mixture was allowed to stir at 80 °C for 18 h. The mixture was then filtered through a small plug of silica with EtOAc (4 × 5 mL), the filtrate was evaporated to dryness, the crude product was purified by column chromatography (hexanes:EtOAc 85:15) to afford 3',5,5'-trimethyl-[1,1'-biphenyl]-3-carbonitrile (**4e**) as an offwhite solid (21.0 mg, 95%). **m. p.** 68-70 °C. **IR**: 2919, 2227, 1598, 1453, 1376, 840, 685 cm⁻¹. ¹**H NMR** (400 MHz, CDCl₃) δ 7.58 (s, 1H), 7.52 (s, 1H), 7.34 (s, 1H), 7.08 (s, 2H), 6.97 (s, 1H), 2.37 (s, 3H), 2.31 (s, 6H) ppm. ¹³C **NMR** (101 MHz, CDCl₃) δ 142.6, 139.5, 139.1, 138.7, 132.4, 130.9, 129.9, 128.0, 125.0, 119.1, 112.6, 21.4, 21.3 ppm. **HRMS**: calcd for C₁₆H₁₆N, 222.1204 (M+H⁺); found, 222.1277.

Silver free arylation of salicylic acids





A mixture of Pd(OAc)₂ (5.6 mg, 0.025 mmol), salicylic acid (69.1 mg, 0.50 mmol), Me₄NCl (68.5 mg, 0.63 mmol), KOAc (98.0 mg, 1.0 mmol), 1-iodo-3,5-dimethylbenzene (218 µL, 1.5 mmol) and acetic acid (43 µL, 0.75 mmol) was heated at 120 °C for 24 h. The mixture was cooled down to room temperature, then extra Me₄NCl (44.0 mg, 0.4 mmol) and KOAc (39.0 mg, 0.4 mmol) were added into the mixture and heated at 120 °C for extra 16 h. After this time, the reaction mixture was filtered through a plug of Celite® with EtOAc (4×5 mL). The filtrate was evaporated to dryness. The crude product was purified by column chromatography (hexanes:EtOAc 90:10) to afford 3',5'-dimethyl-[1,1'-biphenyl]-3-ol (**3aa**) as a light orange oil (59.5 mg, 60%). ¹H NMR (400 MHz, CDCl₃) δ 7.29 (t, *J* = 7.9 Hz, 1H), 7.20 (s, 2H), 7.17-7.15 (m, 1H), 7.07-7.05 (m, 1H), 7.01 (s, 1H), 6.80 (ddd, *J* = 8.0, 2.6, 0.9 Hz, 1H), 4.76 (s, 1H), 2.38 (s, 6H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 155.7, 143.3, 140.8, 138.3, 129.9, 129.1, 125.1, 119.9, 114.1, 114.0, 21.4 ppm. These data are consistent with those previously reported.²

3',4,5'-Trimethyl-[1,1'-biphenyl]-3-ol



A mixture of Pd(OAc)₂ (5.6 mg, 0.025 mmol), 2-hydroxy-3-methylbenzoic acid (76.1 mg, 0.50 mmol), Me₄NC1 (68.5 mg, 0.63 mmol), KOAc (98.0 mg, 1.0 mmol), 1-iodo-3,5-dimethylbenzene (218 μ L, 1.5 mmol) and acetic acid (43 μ L, 0.75 mmol) was heated at 120 °C for 24 h. The mixture was cooled down to room temperature, then extra Me₄NCl (44.0 mg, 0.4 mmol) and KOAc (39.0 mg, 0.4 mmol) were added into the mixture and heated at 120 °C for extra 16 h. After this time, the reaction mixture was filtered through a plug of Celite® with EtOAc (4 × 5 mL). The filtrate was evaporated to dryness. The crude product was purified by column chromatography (hexanes:EtOAc 90:10) to afford 3',4,5'-trimethyl-[1,1'-biphenyl]-3-ol (**3ac**) as an orange oil (59.0 mg, 56%). ¹H NMR (400 MHz, CDCl₃) δ 7.18-7.16 (m, 3H), 7.08 (dd, *J* = 7.7, 1.7 Hz, 1H), 7.01-7.00 (m, 1H), 6.98 (s, 1H), 4.69 (s, 1H), 2.37 (s, 6H), 2.29 (s, 3 H) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 153.9, 140.8, 140.8, 138.2, 131.2, 128.8, 124.9, 122.5, 119.6, 113.7, 21.4, 15.4 ppm. These data are consistent with those previously reported.²

3',5,5'-Trimethyl-[1,1'-biphenyl]-3-ol



A mixture of Pd(OAc)₂ (5.6 mg, 0.025 mmol), 2-hydroxy-4-methylbenzoic acid (76.1 mg, 0.50 mmol), Me₄NCl (68.5 mg, 0.63 mmol), KOAc (98.0 mg, 1.0 mmol), 1-iodo-3,5-dimethylbenzene (218 μ L, 1.5 mmol) and acetic acid (43 μ L, 0.75 mmol) was heated at 120 °C for 24 h. The mixture was cooled down to room temperature, then extra Me₄NCl (44.0 mg, 0.4 mmol) and KOAc (39.0 mg, 0.4 mmol) were added into the mixture and heated at 120 °C for extra 16 h. After this time, the reaction mixture was filtered through a plug of Celite® with EtOAc (4 × 5 mL). The filtrate was evaporated to dryness. The crude product was purified by column chromatography (hexanes:EtOAc 90:10) to afford 3',5,5'-trimethyl-[1,1'-biphenyl]-3-ol (**3ai**) as a light orange solid (74.1 mg, 70%). ¹**H NMR** (400 MHz, CDCl₃) δ 7.18 (s, 2H), 6.99-6.97 (m, 2H), 6.85-6.84 (m, 1H), 6.63 (s, 1H), 4.66 (s, 1H), 2.37 (s, 6H), 2.36 (s, 3H) ppm. ¹³**C NMR** (101 MHz, CDCl₃) δ 155.7, 143.1, 140.9, 139.9, 138.2, 129.0, 125.0, 120.8, 114.8, 111.3, 21.44, 21.37 ppm. These data are consistent with those previously reported.²

References

- (a) C. Ramalingan, I. Lee, Y. Kwak, *Chem. Pharm. Bull.* 2009, 57, 591–596; (b) A. V. Noverola, J. P. Soto, R. G. W. Spickett, *United States Patent*, 4138492.
- 2 J. Luo, S. Preciado and I. Larrosa, J. Am. Chem. Soc., 2014, 136, 4109-4112.
- 3 C. Seong, C. M. Park, S. Kim, W. Park and N. Park, *United States Patent Application Publication*. US 2009/0258876 A1.
- 4 D. Wensbo, T. Stefanac, J. Arora, L. Edwards, M. Isaac and A. Slassi, *World Intellectual Property Organization*. WO 2004/014902 A2.
- 5 L. J. Goossen, N. Rodríguez and C. Linder, J. Am. Chem. Soc., 2008, 130, 15248-15249.
- 6 A. O. Adeniji, B. M. Twenter, M. C. Byrns, Y. Jin, M. Chen, J. D. Winkler and T. M. Penning, J. Med. Chem., 2012, 55, 2311-2323.
- 7 C. Y. HO, United States Patent Application Publication. US 2009/0105288 A1.
- 8 P. Y. Yeung, C. M. So, C. P. Lau and F. Y. Kwong, Angew. Chem. Int. Ed., 2010, 49, 8918-8922.







210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 f1 (ppm)

